Cue Biopharma, Inc. CUE
Set alert
19.42 USD -1.45 -6.95%
At close
19.72 +0.30 +1.54%
Pre-market · Nov 3, 4:07 AM ET
19.12 Day range 21.40
4.98 52-week range 45.50
- YTD
- +112.24%
- 1 year
- -9.84%
- Open
- 20.74
- Prev close
- 20.87
- Mkt cap
- 141.07M
- Vol
- 140.95K
- Avg vol
- 260.61K
- EPS
- -29.59
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.12
- High
- 21.40
- Forward P/E
- -1.79
- Beta
- 1.80
- Short ratio
- 1.54
- Inst. own
- 23.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.31
- 200-d avg
- 1.26
- 1y target
- 3.60
3M chart
Signals (23)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Sep 2, 2026 | 2 months ago |
| SMA: Bullish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
Newest 20 of 23.
Analyst view
Consensus: none
Price target (mean) 3.60 -81.5% downside
Now 19.42
- Target (low)
- 2.00
- Target (mean)
- 3.60
- Target (high)
- 6.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.145 | -0.15 – -0.14 | -0.29 | +50.0% | 1.70M | -6.6% | 2 |
| Next quarter | -0.15 | -0.17 – -0.13 | -0.25 | +40.0% | 1.27M | -26.2% | 2 |
| Current year | -0.755 | -0.77 – -0.74 | -1.11 | +32.0% | 9.41M | +71.4% | 2 |
| Next year | -0.57 | -0.60 – -0.54 | -0.755 | +24.5% | 10.45M | +11.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2024 | Stifel | Maintained | Buy | Buy |
| Jul 26, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Jul 26, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Apr 9, 2024 | Stifel | Maintained | Buy | Buy |
| Apr 9, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Apr 3, 2024 | Piper Sandler | Reiterated | Overweight | Overweight |
| Mar 13, 2024 | Jefferies | Initiated | — | Buy |
| Nov 6, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Jun 15, 2023 | Stifel | Reiterated | Buy | Buy |
| May 15, 2023 | JMP Securities | Reiterated | Outperform | Outperform |
| Mar 22, 2023 | Stifel | Maintained | — | Buy |
| Mar 22, 2023 | Oppenheimer | Reiterated | — | Outperform |
| Nov 21, 2022 | Piper Sandler | Initiated | — | Overweight |
| Aug 24, 2022 | Oppenheimer | Maintained | — | Outperform |
| Mar 21, 2022 | Oppenheimer | Maintained | — | Outperform |
| Mar 18, 2022 | Craig-Hallum | Maintained | — | Buy |
| Nov 24, 2020 | Berenberg | Initiated | — | Buy |
| May 20, 2020 | Stifel | Maintained | — | Buy |
| May 20, 2020 | Oppenheimer | Maintained | — | Outperform |
| Apr 21, 2020 | Stifel | Maintained | — | Buy |
| Apr 9, 2020 | Stifel | Initiated | — | Buy |
| Mar 6, 2020 | JMP Securities | Maintained | — | Outperform |
| Feb 25, 2020 | Oppenheimer | Initiated | — | Outperform |
| Jan 28, 2020 | BTIG | Initiated | — | Buy |
| Jan 22, 2020 | JMP Securities | Initiated | — | Market Outperform |
| Jul 26, 2019 | Baird | Initiated | — | Outperform |